Have two minutes? Listen to this quick podcast for critical takeaways from three of our top articles.
MHE Managed Care Pharmacy Survey
Preparing for pharmacy policy changes can help your managed care organization stay ahead of the competition. Here, pharmacy experts highlight three areas to watch closely.
The International Rare Diseases Research Consortium hopes to develop 200 new drugs for rare diseases by 2020, and it seems as if things are better than on track.
Legislation removes FDA involvement when patients seek experimental medications. Here’s what critics and proponents say.
Some of the most amazing things are happening in the delivery of medical care these days. Surgical techniques, new devices, drugs, and diagnostics can treat and cure many medical conditions.
Congress recently began hearings on proposals to combat opioid abuse. Our policy analyst weighs in.
This might be the year when it becomes clear, perhaps painfully so, whether or not biosimilars can deliver on cost savings expectations.
FDA incentives have hastened the development of “orphan drugs” for rare diseases, but some worry that regulators are not always demanding clear evidence for drug efficacy.
CMS’ 5-Star Rating system requires proactive intervention to improve patient medication adherence, and leaves plans with little room to rest on their laurels.
A University of Massachusetts clinical consulting pharmacist shows how assessing budget implications can be accomplished.